Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy

Experimental and Therapeutic Medicine

Volumn 6, Issue 2, 2013, Pages 567-573

  He, Hongying ^a   Qiao, Xiaoyu ^b   Wu, Suisheng ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Carbamylated erythropoietin; Cardiomyopathy; Cell signal transduction; Diabetes; Phosphatidylinositol 3 kinase Akt

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; CASPASE 3; ERYTHROPOIETIN; HEMOGLOBIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARBAMOYLATION; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ACTIVATION; ERYTHROCYTE COUNT; GENE EXPRESSION; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NICK END LABELING; NONHUMAN; RAT; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 84879678784     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1134     Document Type: Article

References (36)

1. Fonarow GC and Srikanthan P: Diabetic cardiomyopathy. Endocrinol Metab Clin North Am 35: 575-599, 2006.
2. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L and Carter TB: Beyond anemia: the clinical impact of the physiologic effects of erythropoietin. Semin Dial 21: 447-454, 2008.
3. Brines M, Grasso G, Fiordaliso F, et al: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 101: 14907-14912, 2004.
4. Moon C, Krawczyk M, Paik D, et al: Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316: 999-1005, 2006.
5. Coleman TR, Westenfelder C, Tögel FE, et al: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 103: 5965-5970, 2006.
6. Park KD, Mun KC, Chang EJ, Park SB and Kim HC: Inhibition of erythropoietin activity by cyanate. Scand J Urol Nephrol 38: 69-72, 2004.
7. Leist M, Ghezzi P, Grasso G, et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004.
8. Adembri C, Massagrande A, Tani A, et al: Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit Care Med 36: 975-978, 2008.
9. Bianchi R, Brines M, Lauria G, et al: Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 12: 2607-2612, 2006.
10. Fiordaliso F, Chimenti S, Staszewsky L, et al: A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 102: 2046-2051, 2005.
11. Imamura R, Okumi M, Isaka Y, et al: Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 17: 135-141, 2008.
12. Fantacci M, Bianciardi P, Caretti A, et al: Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci USA 103: 17531-17536, 2006.
13. Xu X, Cao Z, Cao B, et al: Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 146: 506-514, 2009.
14. King VR, Averill SA, Hewazy D, Priestley JV, Torup L and Michael-Titus AT: Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 26: 90-100, 2007.
15. Xiong Y, Mahmood A, Zhang Y, et al: Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury. J Neurosurg 114: 549-559, 2011.
16. Moon C, Krawczyk M, Lakatta EG and Talan MI: Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats. Cardiovasc Drugs Ther 20: 245-251, 2006.
17. Robey TE, Saiget MK, Reinecke H and Murry CE: Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol 45: 567-581, 2008.
18. Xu K, George I, Klotz S, et al: Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure. J Cardiovasc Pharmacol 56: 506-512, 2010.
19. Abe T, Isaka Y, Imamura R, et al: Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis. Cell Transplant 21: 571-580, 2012.
20. Imamura R, Isaka Y, Sandoval RM, et al: A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. Clin Exp Nephrol 16: 852-862, 2012.
21. Schmidt RE, Green KG, Feng D, et al: Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 209: 161-170, 2008.
22. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X and Kang YJ: Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48: 1688-1697, 2006.
23. Chen J, Cha-Molstad H, Szabo A and Shalev A: Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab 296: E1133-E1139, 2009.
24. Li JH, Zhang N and Wang JA: Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest 31: 103-110, 2008.
25. Liu HR, Tao L, Gao E, et al: Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation-a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res 81: 344-352, 2009.
26. Bäcklund T, Palojoki E, Saraste A, et al: Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia 47: 325-330, 2004.
27. Chowdhry MF, Vohra HA and Galiñanes M: Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: role of caspases and poly-adenosine diphosphate-ribose polymerase. J Thorac Cardiovasc Surg 134: 124-131. e3, 2007.
28. Xu J, Wang G, Wang Y, Liu Q, Xu W, Tan Y and Cai L: Diabetes-and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection. J Cell Mol Med 13: 1499-1512, 2009.
29. Carrington EM, McKenzie MD, Jansen E, et al: Islet beta-cells deficient in Bcl-xL develop but are abnormally sensitive to apoptotic stimuli. Diabetes 58: 2316-2323, 2009.
30. Morrissy S, Xu B, Aguilar D, Zhang J and Chen QM: Inhibition of apoptosis by progesterone in cardiomyocytes. Aging Cell 9: 799-809, 2010.
31. Matsui T and Davidoff AJ: Assessment of PI-3 kinase and Akt in ischemic heart diseases in diabetes. Methods Mol Med 139: 329-338, 2007.
32. Williams DL, Ozment-Skelton T and Li C: Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock 25: 432-439, 2006.
33. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, et al: Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 294: H724-H735, 2008.
34. Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624, 2005.
35. Westermann D, Van Linthout S, Dhayat S, et al: Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56: 1834-1841, 2007.
36. Bilim O, Takeishi Y, Kitahara T, et al: Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. Cardiovasc Diabetol 7: 2, 2008.